Leadgene Biomedical is proud to announce its recognition by the Small and Medium Enterprise and Starup Administration, Ministry of Economic Affairs, as a recipient of the 32nd Taiwan SMEs Innovation Award. This prestigious honor highlights Leadgene’s exceptional R&D capabilities and groundbreaking innovations in the biotechnology sector.
The award-winning innovation is a novel in vitro diagnostic solution that enables physicians to assess kidney function with greater efficiency and cost-effectiveness. It is the first product globally to receive medical device approvals from Taiwan’s Ministry of Health and Welfare, the European Union, Singapore, and Vietnam for the detection of indoxyl sulfate, a critical biomarker for chronic kidney disease (CKD).
This diagnostic technology provides a more comprehensive approach to kidney function evaluation while enhancing user convenience. Its clinical utility in disease monitoring and management has been validated in multiple peer-reviewed international publications. As such, the solution is poised to become a key enabler in the advancement of precision nephrology.
This award not only affirms the long-standing dedication of our R&D team but also reinforces Leadgene Biomedical’s leadership in precision medicine and biomarker-driven diagnostics.
We remain committed to innovation, product excellence, and global expansion—delivering impactful solutions that improve healthcare outcomes worldwide.
